Dementia and Alzheimer Disease

Prespecified analyses showed that obicetrapib significantly reduced primary outcome measure of Alzheimer disease biomarkers in both the overall population and APOE4 carriers.

Catch up on any of the neurology news headlines you may have missed over the course of May 2025, compiled all into one place by the NeurologyLive® team.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 30, 2025.

AHN Saint Vincent Hospital offers advanced neurological care, reducing wait times and providing local access to specialized treatments for various conditions.

BioVie initiates a phase 2 trial for bezisterim, targeting neurological symptoms of Long COVID, aiming to improve patient quality of life.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 23, 2025.

The assistant professor of neurology at Robert Wood Johnson Medical School discussed the mission of RCASIA, highlights from its annual retreat, and key takeaways from AAN 2025.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 16, 2025.

The FDA approved Fujirebio's Lumipulse G p-tau217/β-Amyloid 1-42 Plasma Ratio as the first in vivo blood test for early Alzheimer’s detection, demonstrating high diagnostic accuracy with strong correlations to amyloid PET and CSF test results.

Targeting tau pathology in preclinical Alzheimer disease could benefit from recruiting individuals positive for both Aß and GFAP biomarkers, improving patient selection and cost effectiveness.

Peter Gliebus, MD, discusses the clinical complexity of frontotemporal dementia and how Baptist Health’s symposium is helping to prepare the field for future advances in diagnosis and treatment.

The phase 2 MAGNIFY trial demonstrated that zervimesine (CT1812) slowed lesion growth in patients with geographic atrophy secondary to dry AMD, showing a 28.6% reduction over 18 months.

Christine Greiss, DO, medical director for the Center for Brain injuries at Hackensack Meridian Health, discussed the nuanced impact of hormonal fluctuations, psychological factors, and postmenopausal status on TBI recovery in women.

Nexalin plans to submit a Q-Submission to the FDA for its Gen-2 SYNC system, aiming to advance trials for Alzheimer disease, dementia, and mild cognitive impairment following positive internal data and FDA feedback.

Moira Kapral, MD, MSc, reflects on her SEQUINS Hall of Fame recognition, the evolution of brain health equity, and her work addressing disparities in stroke care.

Robert J. Adams, MS, MD, reflects on his SEQUINS Hall of Fame recognition, his work on stroke prevention, and the importance of equity in brain health.

Barbara Vickrey, MD, MPH, discusses her SEQUINS Hall of Fame honor, the evolution of healthcare delivery models, and the role of mentorship in fostering equity in neurology.

Lewis B. Morgenstern, MD, reflects on his SEQUINS Hall of Fame recognition, the importance of health equity research, and his ongoing efforts to reduce stroke disparities.

Cheryl Bushnell, MD, MHS, a professor of neurology at Wake Forest University, discussed her SEQUINS Hall of Fame recognition, her work on sex differences in stroke risk, and her ongoing efforts to improve stroke care equity.

The findings support the neuroprotective effects of GLP-1RAs and SGLT2is, suggesting their possible role in Alzheimer disease prevention strategies in people with type 2 diabetes.

The chief of ophthalmology at the Doheny Eye Institute discussed decades of research uncovering how Alzheimer can impact visual function and how retinal imaging may advance diagnosis. [WATCH TIME: 13 minutes]

The neuroradiologist at Mayo Clinic discussed the clinical and conceptual differences between Alzheimer disease diagnostic frameworks and how clinicians should prepare for a shifting treatment landscape. [WATCH TIME: 4 minutes]

Sonya Miller, medical director at TauRx, discussed the latest clinical data and development plans for HMTM, a potential oral therapy targeting tau pathology in Alzheimer disease.

Ken Mariash, chief executive officer at Sinaptica, provided commentary on new data from the company’s SinaptiStim neuromodulation system, highlighting its clinical promise in slowing Alzheimer disease progression through targeted, non-drug brain network stimulation.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 18, 2025.

The resident in the Department of Neurology at NYU Langone Health discussed the preliminary findings of a 9-month study on lecanemab recently presented at the 2025 AAN Annual Meeting. [WATCH TIME: 2 minutes]

A duo of neurology experts from Feinberg School of Medicine talked about the diagnostic challenges, evolving understanding, and clinical implications of paraneoplastic neurological syndromes. [WATCH TIME: 3 minutes]

The professor in the Department of Pathology and Laboratory Medicine at the University of California, Irvine, gave clinical insights on efforts to refine neuropsychological outcome measures for individuals with Down syndrome at risk for Alzheimer disease. [WATCH TIME: 3 minutes]

The chief medical officer at Cognito Therapeutics provided a clinical overview on promising findings surrounding the company’s gamma sensory stimulation device in patients with Alzheimer disease. [WATCH TIME: 10 minutes]

The vice president of research at Cognition Therapeutics provided commentary on the safety of investigational CT1812 and its role in immune response and synapse-related pathways. [WATCH TIME: 3 minutes]